Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor
Medical College of Wisconsin
Study ID
NCT07185204
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Postpartum Preeclampsia

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Early detection and management of postpartum preeclampsia bundle — OTHER
    Remote blood pressure monitoring, education, and dispensing antihypertensive medication (nifedipine ER) for outpatient management of asymptomatic, mild range BP.

Study Details

The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.

Key Dates

Start date
May 31, 2026
Status verified
Mar 2026
Primary completion
Jun 30, 2026
Completion
May 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: High-risk Intervention
    Participants with high-risk sFlt-1/PlGF ratio randomized to early detection and management of postpartum preeclampsia with remote blood pressure monitoring, education, and dispensing antihypertensive medication (nifedipine ER) for outpatient management of asymptomatic, mild range BP.
  • No Intervention: High-Risk Control
    Participants with high-risk sFlt-1/PlGF ratio randomized to standard postpartum care.
  • No Intervention: Low-risk Control
    Participants with low-risk sFlt-1/PlGF ratio will not be randomized, but will remain enrolled to assess the exploratory outcome of biomarker predictive ability.

Primary Outcome Measure

Study feasibility [ Time Frame: 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Medical College of WisconsinMilwaukeeWisconsin53226
Anna Palatnik, MD
[email protected]
414-805-6627
Alyssa Hernandez, DO
[email protected]
4148055285
Anna Palatnik, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Milwaukee, WI

By research site
Medical College of Wisconsin· Milwaukee, WI

Related Studies